Orasure Technologies Inc
OSUR Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2016βFY2025
What Orasure Technologies Inc does
No business description yet.
- Legal name
- ORASURE TECHNOLOGIES INC
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 9, 2026
- Accession Β· CIK
- 0001116463-26-000016
0001116463
Revenue and margins
Orasure Technologies Inc had $115M of revenue in fiscal 2025, down 38.1% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$53.2M in fiscal 2025, β46.3% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Orasure Technologies Inc returned $15.0M to shareholders in fiscal 2025. The diluted share count fell 1.3%.
Balance sheet
Cash, debt and the ratios that show how comfortably Orasure Technologies Inc can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $153M | $111M | $290M | $268M | $199M |
| Current ratio | 4.4x | 4.7x | 9.8x | 10.0x | 6.6x |
| Quick ratio | 3.6x | 3.3x | 8.6x | 8.9x | 5.8x |
| Total assets | $461M | $444M | $483M | $480M | $403M |
| Total liabilities | $80.5M | $79.8M | $52.2M | $69.3M | $62.3M |
| Shareholders' equity | $381M | $364M | $431M | $410M | $341M |
| Net debt (β = net cash) | β | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 8 | 6 / 8 | 3 / 8 | 2 / 8 | 1 / 8 | 3 / 8 | 6 / 8 | 4 / 8 | 2 / 8 |
| Accruals ratio | β2.3% | 1.1% | β6.1% | 2.1% | β5.2% | 2.7% | 6.6% | β19.0% | β9.7% | β4.5% |
| Altman Z'' | 11.52 | 10.91 | 12.80 | 10.84 | 10.21 | 7.26 | 7.24 | 13.27 | 9.22 | 6.76 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $128M | $167M | $182M | $155M | $172M | $234M | $387M | $405M | $186M | $115M |
| Gross profit | $88.0M | $99.0M | $114M | $94.6M | $102M | $118M | $148M | $172M | $79.4M | $48.2M |
| Research and development | $9.8M | $13.4M | $16.3M | $19.6M | $31.0M | $34.2M | $36.2M | $33.7M | $26.0M | $42.5M |
| Operating income | $20.3M | $40.2M | $28.4M | $18.6M | β$5.2M | β$10.2M | β$22.2M | $32.7M | β$28.3M | β$72.0M |
| Pretax income | $20.3M | $41.0M | $31.7M | $21.3M | β$3.5M | β$9.3M | β$15.7M | $56.3M | β$16.0M | β$64.6M |
| Income tax | $0.6M | $10.1M | $11.3M | $4.7M | $11.4M | $13.7M | $1.5M | $2.6M | $1.8M | $1.8M |
| Net income | $19.7M | $30.9M | $20.4M | $16.7M | β$14.9M | β$23.0M | β$17.1M | $53.7M | β$19.5M | β$68.7M |
| Diluted EPS | $0.35 | $0.51 | $0.33 | $0.27 | $0.22 | β$0.32 | β$0.24 | $0.72 | β$0.26 | β$0.94 |
| Diluted shares | 0.06B | 0.06B | 0.06B | 0.06B | 0.07B | 0.07B | 0.07B | 0.07B | 0.07B | 0.07B |
| Cash flow | ||||||||||
| Cash from operations | $24.6M | $28.2M | $39.1M | $9.8M | $5.8M | β$35.4M | β$47.2M | $142M | $27.4M | β$49.0M |
| Capital expenditure | $4.4M | $4.3M | $6.3M | $9.3M | $26.7M | $21.9M | $6.8M | $5.8M | $3.8M | $4.2M |
| Free cash flow | $20.2M | $23.8M | $32.7M | $0.5M | β$20.9M | β$57.3M | β$54.0M | $136M | $23.6M | β$53.2M |
| Depreciation and amortization | $5.7M | $6.1M | $6.5M | $7.3M | $9.4M | $11.7M | $15.3M | $20.9M | $10.9M | $10.2M |
| Stock-based compensation | $6.1M | $7.0M | $15.2M | $4.1M | $7.1M | $7.8M | $11.6M | $10.7M | $11.9M | $10.1M |
| Acquisitions | β | β | β | $23.8M | $3.0M | β | $0.0M | $0.0M | $5.0M | $3.6M |
| Share buybacks | $3.4M | $1.2M | $3.6M | $3.7M | $2.1M | $2.1M | $2.3M | $0.0M | $0.0M | $15.0M |
| Dividends and buybacks | $3.4M | $1.2M | $3.6M | $3.7M | $2.1M | $2.1M | $2.3M | $0.0M | $0.0M | $15.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $119M | $154M | $157M | $156M | $209M | $153M | $111M | $290M | $268M | $199M |
| Finance lease liabilities | β | β | β | $2.0M | $1.4M | $2.9M | $1.7M | $0.8M | $0.2M | $0.2M |
| Current assets | $156M | $222M | $219M | $225M | $289M | $299M | $325M | $386M | $333M | $262M |
| Current liabilities | $17.3M | $32.2M | $28.0M | $32.7M | $46.5M | $68.1M | $69.1M | $39.5M | $33.5M | $39.8M |
| Inventory | $11.8M | $19.3M | $22.9M | $23.2M | $31.9M | $53.1M | $95.7M | $47.6M | $34.2M | $31.1M |
| Property and equipment, net | $20.0M | $21.4M | $24.3M | $30.3M | $51.9M | $73.4M | $59.4M | $45.4M | $45.1M | $39.2M |
| Goodwill | $18.8M | $20.1M | $18.5M | $36.2M | $40.4M | $40.3M | $35.1M | $35.7M | $40.3M | $43.4M |
| Intangible assets | $10.3M | $8.2M | $5.1M | $14.7M | $17.9M | $14.3M | $11.7M | $1.2M | $17.4M | $19.0M |
| Total assets | $208M | $296M | $316M | $349M | $454M | $461M | $444M | $483M | $480M | $403M |
| Total liabilities | $22.1M | $38.1M | $32.2M | $42.2M | $55.9M | $80.5M | $79.8M | $52.2M | $69.3M | $62.3M |
| Preferred stock | β | β | β | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $186M | $258M | $283M | $307M | $399M | $381M | $364M | $431M | $410M | $341M |
| Margins | ||||||||||
| Gross margin | 68.7% | 59.2% | 62.5% | 61.2% | 59.3% | 50.3% | 38.3% | 42.3% | 42.7% | 41.9% |
| Operating margin | 15.8% | 24.1% | 15.6% | 12.0% | β3.0% | β4.3% | β5.7% | 8.1% | β15.2% | β62.6% |
| EBITDA margin | 20.2% | 27.7% | 19.2% | 16.8% | 2.5% | 0.6% | β1.8% | 13.2% | β9.4% | β53.7% |
| Net margin | 15.4% | 18.5% | 11.2% | 10.8% | β8.7% | β9.8% | β4.4% | 13.2% | β10.5% | β59.8% |
| FCF margin | 15.8% | 14.3% | 18.0% | 0.3% | β12.2% | β24.5% | β13.9% | 33.5% | 12.7% | β46.3% |
| Returns | ||||||||||
| Return on capital employed | 10.6% | 15.2% | 9.9% | 5.9% | β1.3% | β2.6% | β5.9% | 7.4% | β6.3% | β19.8% |
| Return on equity | 10.6% | 13.9% | 7.5% | 5.6% | β4.2% | β5.9% | β4.6% | 13.5% | β4.6% | β18.3% |
| Return on assets | 9.5% | 12.3% | 6.7% | 5.0% | β3.7% | β5.0% | β3.8% | 11.6% | β4.1% | β15.6% |
| Return on tangible equity | 12.6% | 13.5% | 7.9% | 6.5% | β4.4% | β7.1% | β5.4% | 13.6% | β5.5% | β24.7% |
| Growth | ||||||||||
| Revenue growth | β | 30.3% | 8.8% | β14.9% | 11.1% | 36.1% | 65.8% | 4.6% | β54.2% | β38.1% |
| Net income growth | β | 56.9% | β34.1% | β18.3% | β189.6% | β | β | β | β136.3% | β |
| EPS growth | β | 45.7% | β35.3% | β18.2% | β18.5% | β245.5% | β | β | β136.1% | β |
| FCF growth | β | 17.7% | 37.5% | β98.5% | β4,358.6% | β | β | β | β82.6% | β325.7% |
| Share count change | β | 8.0% | 2.5% | β0.6% | 8.6% | 6.6% | 0.7% | 2.6% | 0.1% | β1.3% |
| Financial health | ||||||||||
| Current ratio | 9.0x | 6.9x | 7.8x | 6.9x | 6.2x | 4.4x | 4.7x | 9.8x | 10.0x | 6.6x |
| Quick ratio | 8.3x | 6.3x | 7.0x | 6.2x | 5.5x | 3.6x | 3.3x | 8.6x | 8.9x | 5.8x |
| Capital allocation | ||||||||||
| Capex / revenue | 3.4% | 2.6% | 3.5% | 6.0% | 15.5% | 9.4% | 1.7% | 1.4% | 2.0% | 3.6% |
| Stock comp / revenue | 4.7% | 4.2% | 8.4% | 2.6% | 4.2% | 3.3% | 3.0% | 2.6% | 6.4% | 8.8% |
| Payouts / FCF | 17.0% | 5.2% | 11.0% | 757.6% | β | β | β | 0.0% | 0.0% | β |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 6.0 | 3.0 | 2.0 | 1.0 | 3.0 | 6.0 | 4.0 | 2.0 |
| Altman Z'' | 11.5 | 10.9 | 12.8 | 10.8 | 10.2 | 7.3 | 7.2 | 13.3 | 9.2 | 6.8 |
| Accruals ratio | β2.3% | 1.1% | β6.1% | 2.1% | β5.2% | 2.7% | 6.6% | β19.0% | β9.7% | β4.5% |
Source: SEC EDGAR XBRL filings (CIK 0001116463). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.